Drugs / KRAS TCR-Transduced PBL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06253520 | May 2024 → Feb 2029 expected | breast cancer, colorectal cancer, malignant urinary system neoplasm, metastatic neoplasm +2 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06690281 | Sep 2025 | cholangiocarcinoma, colorectal cancer, duodenum cancer, hepatocellular carcinoma +2 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRAS TCR-Transduced PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253520 ↗ |
| Action | Deplete | “These neoantigen TCR gene-modified cells can recognize and destroy the autologous cancer in vitro.” NCT06253520 ↗ |
| Modality | Cell therapy | “T-cell receptors that recognize KRAS G12D or G12V mutations will be inserted into participant PBL and used for cell transfer immunotherapy.” NCT06253520 ↗ |
| Route | Intravenous | “Cells will be infused intravenously (IV)” NCT06253520 ↗ |
| Target | KRAS | “T-cell receptors that recognize KRAS G12D or G12V mutations” NCT06253520 ↗ |